TerminatedPhase 2NCT00069992

Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML

Studying Acute myeloid leukemia with 11q23 abnormalities

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Baylor College of Medicine
Principal Investigator
George Carrum, MD
Baylor College of Medicine
Intervention
Total Body Irradiation(radiation)
Enrollment
7 enrolled
Eligibility
All sexes
Timeline
20012007

Study locations (2)

Collaborators

The Methodist Hospital Research Institute · Center for Cell and Gene Therapy, Baylor College of Medicine

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00069992 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia with 11q23 abnormalities

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia with 11q23 abnormalities

← Back to all trials